Trifluridine
drugOn this page
Also known as F3dthdNSC-529182NSC-75520T.f.t.TrifluridinaTrifluridine component of lonsurfTrifluridine component of s-95005Trifluridine component of tas-102TriherpineViropticTrifluoromethyl DeoxyuridineSID26748925SID56463177SID8139891trifluorothymidineSID29218081SID131404691SID144205964SID56422883
Summary
Trifluridine (CHEMBL1129) is an approved small-molecule antiviral drug (ATC L01BC59); indicated across 17 conditions including neoplasm and colorectal adenocarcinoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: L01BC59 (+1 more)
- Indications: 17 conditions
- Clinical trials: 87
- Chemistry: 296.2 Da · C10H11F3N2O5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1129 |
| Name | Trifluridine |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 6256 |
| ChEBI | CHEBI:75179 |
| ATC | L01BC59, S01AD02 |
| Molecular formula | C10H11F3N2O5 |
| Molecular weight | 296.2 |
| InChIKey | VSQQQLOSPVPRAZ-RRKCRQDMSA-N |
SMILES: C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
IUPAC name: 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
ChEBI definition: A pyrimidine 2’-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.
Pharmacological roles (ChEBI): antiviral drug, EC 2.1.1.45 (thymidylate synthase) inhibitor, antineoplastic agent.
Other ChEBI roles (chemical / environmental): antimetabolite.
Also known as: F3dthd, NSC-529182, NSC-75520, T.f.t., Trifluridina, Trifluridine, Trifluridine component of lonsurf, Trifluridine component of s-95005, Trifluridine component of tas-102, Triherpine, Viroptic, Trifluoromethyl Deoxyuridine
Patent coverage: 6,837 distinct patent families (24,647 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Survival motor neuron protein, Prelamin-A/C, Inositol monophosphatase 1, Latent membrane protein 1, Beta-lactamase, Alpha-1A adrenergic receptor, Thymidylate kinase, Polyunsaturated fatty acid lipoxygenase ALOX12.
Bioactivity
ChEMBL activities: 5 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P03230 | 5.95 | AC50 | 1130 | nM | CHEMBL_ACT_7471769 |
| P03230 | 5.82 | AC50 | 1506 | nM | CHEMBL_ACT_7362588 |
| LMNA | 5.7 | Potency | 1995 | nM | CHEMBL_ACT_3644013 |
| P97697 | 5.35 | Potency | 4467 | nM | CHEMBL_ACT_4412388 |
| P00811 | 5.25 | Potency | 5623 | nM | CHEMBL_ACT_4666356 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
17 indications (8 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| colorectal adenocarcinoma | 4 | MONDO:0005008 | EFO:0000365 |
| colorectal carcinoma | 4 | MONDO:0024331 | EFO:1001951 |
| eye infectious disorder | 4 | MONDO:0043885 | EFO:1001888 |
| colorectal neoplasm | 4 | MONDO:0005335 | EFO:0004142 |
| herpes simplex infectious disease | 4 | MONDO:0004609 | EFO:1002022 |
| keratoconjunctivitis | 4 | MONDO:0004768 | MONDO:0004768 |
| rectal cancer | 2 | MONDO:0006519 | EFO:1000657 |
| cholangiocarcinoma | 2 | MONDO:0019087 | EFO:0005221 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| rectal neoplasm | 2 | MONDO:0002165 | MONDO:0044937 |
| colon carcinoma | 2 | MONDO:0002032 | EFO:1001950 |
| gastric adenocarcinoma | 1 | MONDO:0005036 | EFO:0000503 |
| non-small cell lung carcinoma | 1 | MONDO:0005233 | EFO:0003060 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 87.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 39 |
| PHASE3 | 14 |
| PHASE1 | 13 |
| PHASE1/PHASE2 | 11 |
| Not specified | 9 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03869892 | PHASE3 | ACTIVE_NOT_RECRUITING | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. |
| NCT04879368 | PHASE3 | ACTIVE_NOT_RECRUITING | RegoNivo vs Standard of Care Chemotherapy in AGOC |
| NCT06197425 | PHASE3 | RECRUITING | Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer |
| NCT06343116 | PHASE3 | NOT_YET_RECRUITING | Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer |
| NCT06992648 | PHASE3 | RECRUITING | Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer |
| NCT07270991 | PHASE3 | RECRUITING | Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma |
| NCT07483684 | PHASE3 | NOT_YET_RECRUITING | A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs |
| NCT07525206 | PHASE3 | NOT_YET_RECRUITING | A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer |
| NCT07549412 | PHASE3 | RECRUITING | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) |
| NCT03306394 | PHASE3 | COMPLETED | A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic). |
| NCT04457297 | PHASE3 | COMPLETED | Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection |
| NCT04737187 | PHASE3 | COMPLETED | Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients |
| NCT05198934 | PHASE3 | COMPLETED | Sotorasib and Panitumumab Versus Investigator’s Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation |
| NCT05223673 | PHASE3 | TERMINATED | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer |
| NCT03368963 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | TAS102 in Combination With NAL-IRI in Advanced GI Cancers |
| NCT03844620 | PHASE2 | ACTIVE_NOT_RECRUITING | Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer |
| NCT04166604 | PHASE2 | ACTIVE_NOT_RECRUITING | LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy |
| NCT04294264 | PHASE2 | ACTIVE_NOT_RECRUITING | TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer |
| NCT04564898 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. |
| NCT04660760 | PHASE2 | RECRUITING | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer |
| NCT05007132 | PHASE2 | RECRUITING | Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer |
| NCT05083481 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors |
| NCT05201352 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine |
| NCT05476796 | PHASE2 | RECRUITING | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer |
| NCT05919264 | PHASE1/PHASE2 | RECRUITING | FOG-001 in Locally Advanced or Metastatic Solid Tumors |
| NCT05927857 | PHASE1/PHASE2 | RECRUITING | Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . |
| NCT05965531 | PHASE2 | RECRUITING | Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy |
| NCT05970705 | PHASE2 | RECRUITING | Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC |
| NCT06242067 | PHASE2 | RECRUITING | Second-line Treatment of Metastatic Colorectal Cancer |
| NCT06485713 | PHASE2 | RECRUITING | Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC |
| NCT06711471 | PHASE2 | RECRUITING | Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer |
| NCT06856837 | PHASE2 | RECRUITING | - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases |
| NCT06872606 | PHASE2 | NOT_YET_RECRUITING | Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer |
| NCT07012954 | PHASE1/PHASE2 | RECRUITING | ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC |
| NCT07071844 | PHASE2 | NOT_YET_RECRUITING | BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients |
| NCT07085169 | PHASE2 | RECRUITING | Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC |
| NCT07146646 | PHASE2 | RECRUITING | Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer |
| NCT07261709 | PHASE2 | NOT_YET_RECRUITING | Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial |
| NCT07280377 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab |
| NCT07381764 | PHASE2 | NOT_YET_RECRUITING | ROMANCE: Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 4 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).